Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research note published on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Trading Up 4.0 %

NASDAQ:TRVN opened at $2.07 on Friday. The company has a market capitalization of $37.97 million, a P/E ratio of -0.77 and a beta of 1.02. The business’s 50-day moving average is $3.77 and its 200 day moving average is $6.41. Trevena has a 12 month low of $1.13 and a 12 month high of $19.23.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($9.25) by $9.02. The firm had revenue of $0.33 million for the quarter. On average, research analysts forecast that Trevena will post -32.25 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.